Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	arachidonate 14,15-epoxygenase activity	CYP2C19 CYP2C9 CYP4Z1	3.95e-06	5	148	3	GO:0008404
GeneOntologyMolecularFunction	(R)-limonene 6-monooxygenase activity	CYP2C19 CYP2C9	5.46e-05	2	148	2	GO:0052741
GeneOntologyMolecularFunction	(S)-limonene 6-monooxygenase activity	CYP2C19 CYP2C9	5.46e-05	2	148	2	GO:0018675
GeneOntologyMolecularFunction	(S)-limonene 7-monooxygenase activity	CYP2C19 CYP2C9	5.46e-05	2	148	2	GO:0018676
GeneOntologyMolecularFunction	limonene monooxygenase activity	CYP2C19 CYP2C9	5.46e-05	2	148	2	GO:0019113
GeneOntologyMolecularFunction	transmembrane transporter activity	CACNA1S TMEM241 SLC27A6 CLIC3 SLC13A3 PKD1L2 ABCC6 RYR3 CHRND SLC35D1 MFSD14A SLC38A2 CLCA1 SLC30A5 CLCNKA CLCNKB ABCA6 P2RX2 AP4M1 SLC4A4 TMEM63A	1.67e-04	1180	148	21	GO:0022857
GeneOntologyMolecularFunction	oxidoreductase activity, acting on CH or CH2 groups	CYP2C19 CYP2C9 XDH	1.70e-04	15	148	3	GO:0016725
GeneOntologyMolecularFunction	myosin heavy chain binding	AMPD1 MYL2 MYL3	2.51e-04	17	148	3	GO:0032036
GeneOntologyMolecularFunction	arachidonate 11,12-epoxygenase activity	CYP2C19 CYP2C9	3.24e-04	4	148	2	GO:0008405
GeneOntologyMolecularFunction	linoleic acid epoxygenase activity	CYP2C19 CYP2C9	3.24e-04	4	148	2	GO:0071614
GeneOntologyMolecularFunction	fatty acid omega-1 hydroxylase activity	CYP2C19 CYP2C9	5.38e-04	5	148	2	GO:0120502
GeneOntologyMolecularFunction	long-chain fatty acid omega-1 hydroxylase activity	CYP2C19 CYP2C9	5.38e-04	5	148	2	GO:0120319
GeneOntologyMolecularFunction	UDP-N-acetylglucosamine transmembrane transporter activity	TMEM241 SLC35D1	5.38e-04	5	148	2	GO:0005462
GeneOntologyMolecularFunction	transporter activity	CACNA1S TMEM241 SLC27A6 CLIC3 SLC13A3 PKD1L2 ABCC6 RYR3 CHRND SLC35D1 MFSD14A SLC38A2 CLCA1 SLC30A5 CLCNKA CLCNKB ABCA6 P2RX2 AP4M1 SLC4A4 TMEM63A	5.46e-04	1289	148	21	GO:0005215
GeneOntologyMolecularFunction	arachidonate epoxygenase activity	CYP2C19 CYP2C9 CYP4Z1	7.20e-04	24	148	3	GO:0008392
GeneOntologyMolecularFunction	intramolecular oxidoreductase activity, interconverting aldoses and ketoses	GPI MPI	8.03e-04	6	148	2	GO:0016861
GeneOntologyMolecularFunction	arachidonate monooxygenase activity	CYP2C19 CYP2C9 CYP4Z1	1.02e-03	27	148	3	GO:0008391
GeneOntologyMolecularFunction	nickel cation binding	P2RX2 FHIT	1.48e-03	8	148	2	GO:0016151
GeneOntologyMolecularFunction	oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor	CYP2C19 CYP2C9	1.48e-03	8	148	2	GO:0033695
GeneOntologyMolecularFunction	caffeine oxidase activity	CYP2C19 CYP2C9	1.48e-03	8	148	2	GO:0034875
Domain	6PGD_dom_2	GPD1 CRYL1 HADH	4.86e-05	10	141	3	IPR013328
Domain	-	GPD1 CRYL1 HADH	4.86e-05	10	141	3	1.10.1040.10
Domain	ARM-type_fold	MYBBP1A DNAJC13 INTS1 PPP6R1 TRRAP RYR3 PPP4R3A THADA HEATR6 AP4B1 AGBL1	5.40e-05	339	141	11	IPR016024
Domain	3-OHacyl-CoA_DH	CRYL1 HADH	5.66e-05	2	141	2	IPR022694
Domain	Cl_channel-K	CLCNKA CLCNKB	5.66e-05	2	141	2	IPR002250
Domain	3HC_DH_C	CRYL1 HADH	3.36e-04	4	141	2	IPR006108
Domain	3HCDH	CRYL1 HADH	3.36e-04	4	141	2	PS00067
Domain	3HCDH	CRYL1 HADH	3.36e-04	4	141	2	PF00725
Domain	3-OHacyl-CoA_DH_NAD-bd	CRYL1 HADH	3.36e-04	4	141	2	IPR006176
Domain	3-OHacyl-CoA_DH_CS	CRYL1 HADH	3.36e-04	4	141	2	IPR006180
Domain	3HCDH_N	CRYL1 HADH	3.36e-04	4	141	2	PF02737
Domain	6-PGluconate_DH_C-like	GPD1 CRYL1 HADH	3.74e-04	19	141	3	IPR008927
Domain	TPR-like_helical_dom	ST7 TTC21A BBS4 COPS3 TRRAP LRPPRC PEX5 PDCD11	3.97e-04	233	141	8	IPR011990
Pubmed	LCP1 preferentially binds clasped αMβ2 integrin and attenuates leukocyte adhesion under flow.	GPI DHX36 XDH CBL TRRAP PHKB MYOF HADH PCBP1 PCBP2 NCKAP1L	2.89e-07	344	148	11	30333137
Pubmed	A BioID-Derived Proximity Interactome for SARS-CoV-2 Proteins.	ZDHHC2 MYL2 COMT AGPAT1 TRRAP SPG21 FANCA JAK1 THADA SLC30A5 CDC42EP2 PEX5 ALG3 FLRT3 HADH	4.83e-07	719	148	15	35337019
Pubmed	GREB1: An evolutionarily conserved protein with a glycosyltransferase domain links ERα glycosylation and stability to cancer.	DHX36 MYBBP1A DNAJC13 PABPC4 JAK1 LRPPRC PRMT5 PCBP1 PCBP2	5.28e-07	223	148	9	33731348
Pubmed	Systematic Analysis of Human Protein Phosphatase Interactions and Dynamics.	GPI MYBBP1A PABPC4 INTS1 PSMC3 PPP6R1 DBT PPP4R3A POLR3A MET PHKB LRPPRC SNRPB2	1.16e-06	573	148	13	28330616
Pubmed	Systematic proteomics of endogenous human cohesin reveals an interaction with diverse splicing factors and RNA-binding proteins required for mitotic progression.	SETX INTS1 TRRAP MYOF LRPPRC PRMT5 PDCD11 PCBP1 PCBP2	2.73e-06	272	148	9	31010829
Pubmed	Genetic mapping of the murine gene and 14 related sequences encoding chromosomal protein HMG-14.	GPI CYP2C19 CYP2C9 MPI	3.13e-06	24	148	4	1360278
Pubmed	Identification and genetic mapping of 151 dispersed members of 16 ribosomal protein multigene families in the mouse.	GPD1 GPI CYP2C19 CYP2C9 MPI	3.82e-06	55	148	5	7873877
Pubmed	Localization of genes for two members of the JAK family of protein tyrosine kinases to murine chromosomes 4 and 19.	CYP2C19 CYP2C9 JAK1	6.23e-06	9	148	3	7613027
Pubmed	Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in β-Catenin-Active Cancers.	CDK8 GPI DHX36 MED18 MYBBP1A COMT PABPC4 PSMC3 PPP6R1 DBT USP14 CRYL1 MYOF LRPPRC PRMT5 SNRPB2 PCBP1 PCBP2	6.43e-06	1247	148	18	27684187
Pubmed	Suppression of atrial myosin gene expression occurs independently in the left and right ventricles of the developing mouse heart.	MYL2 MYL3 DNAH11	8.87e-06	10	148	3	10679931
Pubmed	Characterization of SARS-CoV-2 proteins reveals Orf6 pathogenicity, subcellular localization, host interactions and attenuation by Selinexor.	MYBBP1A PABPC4 PSMC3 PPP6R1 JAK1 LRPPRC PRMT5 VPS13A PCBP1 PCBP2	1.07e-05	408	148	10	33766124
Pubmed	C5orf51 is a component of the MON1-CCZ1 complex and controls RAB7A localization and stability during mitophagy.	DNAJC13 WASHC4 ST7 SPG21 SLC38A2 SLC30A5 VPS13A TMEM131L FNIP1 RMC1 EIF2AK3	1.14e-05	504	148	11	34432599
Pubmed	Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.	CYP2C19 CYP2C9 MYL10	1.62e-05	12	148	3	24528284
Pubmed	Characterisation of two major cellular poly(rC)-binding human proteins, each containing three K-homologous (KH) domains.	PCBP1 PCBP2	1.80e-05	2	148	2	7607214
Pubmed	The ClC-K2 Chloride Channel Is Critical for Salt Handling in the Distal Nephron.	CLCNKA CLCNKB	1.80e-05	2	148	2	27335120
Pubmed	Assignment of the genes encoding the human chloride channels, CLCNKA and CLCNKB, to 1p36 and of CLCN3 to 4q32-q33 by in situ hybridization.	CLCNKA CLCNKB	1.80e-05	2	148	2	8812470
Pubmed	αCP Poly(C) binding proteins act as global regulators of alternative polyadenylation.	PCBP1 PCBP2	1.80e-05	2	148	2	23629627
Pubmed	Associations between CLCNKA_B tag SNPs with essential hypertension and interactions between genetic and environmental factors in an island population in China.	CLCNKA CLCNKB	1.80e-05	2	148	2	25919862
Pubmed	Important amino acid residues that confer CYP2C19 selective activity to CYP2C9.	CYP2C19 CYP2C9	1.80e-05	2	148	2	18511451
Pubmed	The competing endogenous RNA network of CYP4Z1 and pseudogene CYP4Z2P exerts an anti-apoptotic function in breast cancer.	CYP4Z1 CYP4Z2P	1.80e-05	2	148	2	28236635
Pubmed	Developmental expression of human hepatic CYP2C9 and CYP2C19.	CYP2C19 CYP2C9	1.80e-05	2	148	2	14634042
Pubmed	CYP2C40, a unique arachidonic acid 16-hydroxylase, is the major CYP2C in murine intestinal tract.	CYP2C19 CYP2C9	1.80e-05	2	148	2	10908295
Pubmed	Oxygenation mechanism in conversion of aldehyde to carboxylic acid catalyzed by a cytochrome P-450 isozyme.	CYP2C19 CYP2C9	1.80e-05	2	148	2	1847130
Pubmed	Cytochromes P450 catalyze oxidation of alpha,beta-unsaturated aldehydes.	CYP2C19 CYP2C9	1.80e-05	2	148	2	17599801
Pubmed	Distinct poly(rC) binding protein KH domain determinants for poliovirus translation initiation and viral RNA replication.	PCBP1 PCBP2	1.80e-05	2	148	2	12414943
Pubmed	Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.	CYP2C19 CYP2C9	1.80e-05	2	148	2	15385837
Pubmed	[Effect of original and generic clopidogrel on prognosis in relation to different gene polymorphisms].	CYP2C19 CYP2C9	1.80e-05	2	148	2	25518510
Pubmed	Splicing factor poly(rC)-binding protein 1 is a novel and distinctive tumor suppressor.	PCBP1 PCBP2	1.80e-05	2	148	2	30132844
Pubmed	An adjacent arginine, and the phosphorylated tyrosine in the c-Met receptor target sequence, dictates the orientation of c-Cbl binding.	CBL MET	1.80e-05	2	148	2	21163258
Pubmed	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.	CYP2C19 CYP2C9	1.80e-05	2	148	2	15842554
Pubmed	Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test.	CYP2C19 CYP2C9	1.80e-05	2	148	2	19136640
Pubmed	Expanding Genotype-Phenotype Correlation of CLCNKA and CLCNKB Variants Linked to Hearing Loss.	CLCNKA CLCNKB	1.80e-05	2	148	2	38069401
Pubmed	Mouse Cyp2c expression and zonation structure in the liver begins in the early neonatal stage.	CYP2C19 CYP2C9	1.80e-05	2	148	2	35748067
Pubmed	Time serial transcriptome reveals Cyp2c29 as a key gene in hepatocellular carcinoma development.	CYP2C19 CYP2C9	1.80e-05	2	148	2	32587777
Pubmed	Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma.	CYP4Z1 CYP4Z2P	1.80e-05	2	148	2	15059886
Pubmed	Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.	CYP2C19 CYP2C9	1.80e-05	2	148	2	17201743
Pubmed	CYP2C9 (2&3) and CYP2C19 (2&3) polymorphisms among children with nonlesional epilepsy: a single-center study.	CYP2C19 CYP2C9	1.80e-05	2	148	2	32683556
Pubmed	Evaluation of phenytoin dosage regimens based on genotyping of CYP2C subfamily in routinely treated Japanese patients.	CYP2C19 CYP2C9	1.80e-05	2	148	2	15855721
Pubmed	The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects.	CYP2C19 CYP2C9	1.80e-05	2	148	2	19847408
Pubmed	CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.	CYP2C19 CYP2C9	1.80e-05	2	148	2	17504998
Pubmed	Cytochrome P450 2C epoxygenases mediate photochemical stress-induced death of photoreceptors.	CYP2C19 CYP2C9	1.80e-05	2	148	2	24519941
Pubmed	Mouse liver CYP2C39 is a novel retinoic acid 4-hydroxylase. Its down-regulation offers a molecular basis for liver retinoid accumulation and fibrosis in aryl hydrocarbon receptor-null mice.	CYP2C19 CYP2C9	1.80e-05	2	148	2	14623888
Pubmed	Rapid testing of clopidogrel resistance by genotyping of CYP2C19 and CYP2C9 polymorphisms using denaturing on-chip capillary electrophoresis.	CYP2C19 CYP2C9	1.80e-05	2	148	2	22589111
Pubmed	A regulatory calcium-binding site at the subunit interface of CLC-K kidney chloride channels.	CLCNKA CLCNKB	1.80e-05	2	148	2	20805576
Pubmed	CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population.	CYP2C19 CYP2C9	1.80e-05	2	148	2	15660966
Pubmed	Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.	CYP2C19 CYP2C9	1.80e-05	2	148	2	18154472
Pubmed	Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.	CYP2C19 CYP2C9	1.80e-05	2	148	2	27353638
Pubmed	Identification of two KH domain proteins in the alpha-globin mRNP stability complex.	PCBP1 PCBP2	1.80e-05	2	148	2	7556077
Pubmed	Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.	CYP2C19 CYP2C9	1.80e-05	2	148	2	17298483
Pubmed	Analysis of the Potential Association of Drug-Metabolizing Enzymes CYP2C93 and CYP2C193 Gene Variations With Type 2 Diabetes: A Case-Control Study.	CYP2C19 CYP2C9	1.80e-05	2	148	2	33115391
Pubmed	Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.	CYP2C19 CYP2C9	1.80e-05	2	148	2	17562299
Pubmed	Prevalence of CYP2C9 and CYP2C19 variants and the impact on clopidogrel efficacy in patients having CYPC19*2 variant.	CYP2C19 CYP2C9	1.80e-05	2	148	2	36960518
Pubmed	Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.	CYP2C19 CYP2C9	1.80e-05	2	148	2	26690534
Pubmed	Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.	CYP2C19 CYP2C9	1.80e-05	2	148	2	19199010
Pubmed	Myosin light chain mutations in familial hypertrophic cardiomyopathy: phenotypic presentation and frequency in Danish and South African populations.	MYL2 MYL3	1.80e-05	2	148	2	11748309
Pubmed	A comparative analysis of binding sites between mouse CYP2C38 and CYP2C39 based on homology modeling, molecular dynamics simulation and docking studies.	CYP2C19 CYP2C9	1.80e-05	2	148	2	19358898
Pubmed	Salt wasting and deafness resulting from mutations in two chloride channels.	CLCNKA CLCNKB	1.80e-05	2	148	2	15044642
Pubmed	αCP binding to a cytosine-rich subset of polypyrimidine tracts drives a novel pathway of cassette exon splicing in the mammalian transcriptome.	PCBP1 PCBP2	1.80e-05	2	148	2	26896798
Pubmed	Cyp2c-deficiency depletes muricholic acids and protects against high-fat diet-induced obesity in male mice but promotes liver damage.	CYP2C19 CYP2C9	1.80e-05	2	148	2	34438105
Pubmed	Chromosomal organization of the cytochrome P450-2C gene family in the mouse: a locus associated with constitutive aryl hydrocarbon hydroxylase.	CYP2C19 CYP2C9	1.80e-05	2	148	2	2895926
Pubmed	Two highly homologous members of the ClC chloride channel family in both rat and human kidney.	CLCNKA CLCNKB	1.80e-05	2	148	2	8041726
Pubmed	Licochalcone A Promotes the Ubiquitination of c-Met to Abrogate Gefitinib Resistance.	CBL MET	1.80e-05	2	148	2	35309168
Pubmed	Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers.	CYP2C19 CYP2C9	1.80e-05	2	148	2	20831536
Pubmed	A cytoplasmic domain mutation in ClC-Kb affects long-distance communication across the membrane.	CLCNKA CLCNKB	1.80e-05	2	148	2	18648499
Pubmed	Cloning, tissue distribution, and intrarenal localization of ClC chloride channels in human kidney.	CLCNKA CLCNKB	1.80e-05	2	148	2	8544406
Pubmed	Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.	CBL MET	1.80e-05	2	148	2	27244893
Pubmed	CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.	CYP2C19 CYP2C9	1.80e-05	2	148	2	16198656
Pubmed	[Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].	CYP2C19 CYP2C9	1.80e-05	2	148	2	15569425
Pubmed	Poly(rC) binding protein 2 binds to stem-loop IV of the poliovirus RNA 5' noncoding region: identification by automated liquid chromatography-tandem mass spectrometry.	PCBP1 PCBP2	1.80e-05	2	148	2	8855318
Pubmed	Targeting kidney CLC-K channels: pharmacological profile in a human cell line versus Xenopus oocytes.	CLCNKA CLCNKB	1.80e-05	2	148	2	24863058
Pubmed	Overt nephrogenic diabetes insipidus in mice lacking the CLC-K1 chloride channel.	CLCNKA CLCNKB	1.80e-05	2	148	2	9916798
Pubmed	Kidney kinetics and chloride ion pumps.	CLCNKA CLCNKB	1.80e-05	2	148	2	9916791
Pubmed	A Complete Absence of Missense Mutation in Myosin Regulatory and Essential Light Chain Genes of South Indian Hypertrophic and Dilated Cardiomyopathies.	MYL2 MYL3	1.80e-05	2	148	2	30605904
Pubmed	The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1.	CYP4Z1 CYP4Z2P	1.80e-05	2	148	2	25701119
Pubmed	Systematic analysis of the regulatory and essential myosin light chain genes: genetic variants and mutations in hypertrophic cardiomyopathy.	MYL2 MYL3	1.80e-05	2	148	2	12404107
Pubmed	An association between the rs1799853 and rs1057910 polymorphisms of CYP2C9, the rs4244285 polymorphism of CYP2C19 and the prevalence rates of drug-resistant epilepsy in children.	CYP2C19 CYP2C9	1.80e-05	2	148	2	32567426
Pubmed	Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis.	CYP2C19 CYP2C9	1.80e-05	2	148	2	17868191
Pubmed	Impact of CYP2C19 and CYP2C9 gene polymorphisms on sodium valproate plasma concentration in patients with epilepsy.	CYP2C19 CYP2C9	1.80e-05	2	148	2	32868386
Pubmed	Evidence for a founder effect for pseudoxanthoma elasticum in the Afrikaner population of South Africa.	ABCC6 FANCA	1.80e-05	2	148	2	12384774
Pubmed	CYP2C9 and CYP2C19 Allele and Haplotype Distributions in Four Mestizo Populations from Western Mexico: An Interethnic Comparative Study.	CYP2C19 CYP2C9	1.80e-05	2	148	2	27617498
Pubmed	Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India.	CYP2C19 CYP2C9	1.80e-05	2	148	2	16873909
Pubmed	Comparison of the in vitro mutagenicity and metabolism of dimethylnitrosamine and benzo[a]pyrene in tissues from inbred mice treated with phenobarbital, 3-methylcholanthrene or polychlorinated biphenyls.	CYP2C19 CYP2C9	1.80e-05	2	148	2	106274
Pubmed	Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study.	CYP2C19 CYP2C9	1.80e-05	2	148	2	15776277
Pubmed	Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.	ST7 PRMT5	1.80e-05	2	148	2	24453002
Pubmed	Effect of cytochrome P450 2C19 and 2C9 amino acid residues 72 and 241 on metabolism of tricyclic antidepressant drugs.	CYP2C19 CYP2C9	1.80e-05	2	148	2	24492587
Pubmed	Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days.	CYP2C19 CYP2C9	1.80e-05	2	148	2	16232205
Pubmed	Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China.	CYP2C19 CYP2C9	1.80e-05	2	148	2	20845310
Pubmed	Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid.	CYP2C19 CYP2C9	1.80e-05	2	148	2	9721182
Pubmed	A set of highly conserved RNA-binding proteins, alphaCP-1 and alphaCP-2, implicated in mRNA stabilization, are coexpressed from an intronless gene and its intron-containing paralog.	PCBP1 PCBP2	1.80e-05	2	148	2	10455157
Pubmed	Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation.	CBL MET	1.80e-05	2	148	2	24440350
Pubmed	Phosphorylation of the MET receptor on juxtamembrane tyrosine residue 1001 inhibits its caspase-dependent cleavage.	CBL MET	1.80e-05	2	148	2	19450681
Pubmed	Cytochrome P450 polymorphisms in patients with Behcet's disease.	CYP2C19 CYP2C9	1.80e-05	2	148	2	17269966
Pubmed	Metabolism of (+)- and (-)-limonenes to respective carveols and perillyl alcohols by CYP2C9 and CYP2C19 in human liver microsomes.	CYP2C19 CYP2C9	1.80e-05	2	148	2	11950794
Pubmed	Mediator MED18 subunit plays a negative role in transcription via the CDK/cyclin module.	CDK8 MED18	1.80e-05	2	148	2	24840924
Pubmed	Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI).	CYP2C19 CYP2C9	1.80e-05	2	148	2	17279092
Pubmed	Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin-Induced Cutaneous Adverse Drug Reactions.	CYP2C19 CYP2C9	1.80e-05	2	148	2	32216088
Pubmed	cDNA cloning and sequence of CYP2C29 encoding P-450 MUT-2, a microsomal aldehyde oxygenase.	CYP2C19 CYP2C9	1.80e-05	2	148	2	8130255
Pubmed	Membrane integration of recombinant human P450 forms.	CYP2C19 CYP2C9	1.80e-05	2	148	2	19534586
Pubmed	A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation.	CBL MET	1.80e-05	2	148	2	15123609
Pubmed	Inter-phenotypic differences in CYP2C9 and CYP2C19 metabolism: Bayesian meta-regression of human population variability in kinetics and application in chemical risk assessment.	CYP2C19 CYP2C9	1.80e-05	2	148	2	33232775
Interaction	AVPR2 interactions	COMT DPY19L1 ST7 INTS1 FANCA THADA SLC30A5 ALG3	2.46e-06	123	141	8	int:AVPR2
Cytoband	6p22.2-p21.31	OR12D2 OR12D1	1.03e-04	5	148	2	6p22.2-p21.31
Cytoband	10q24	CYP2C19 CYP2C9 MYOF	1.99e-04	35	148	3	10q24
GeneFamily	Myosin light chains\|EF-hand domain containing	MYL2 MYL3 MYL10	5.38e-05	14	98	3	657
GeneFamily	Olfactory receptors, family 12	OR12D2 OR12D1	8.69e-05	3	98	2	160
GeneFamily	Chloride voltage-gated channels	CLCNKA CLCNKB	1.27e-03	10	98	2	302
Coexpression	LEE_CALORIE_RESTRICTION_MUSCLE_UP	GPD1 CYP2C19 CYP2C9 PSMC3 PEX5	3.93e-06	43	145	5	MM669
Coexpression	GSE3982_EOSINOPHIL_VS_DC_UP	CACNA1S VN1R1 DENND3 RLF JAK1 GVINP1 TMEM131L FLRT3	1.57e-05	199	145	8	M5399
Coexpression	GSE27670_CTRL_VS_LMP1_TRANSDUCED_GC_BCELL_DN	ANK1 XDH CRYL1 LRPPRC CLCA1 PEX5 HADH RAB3IL1	1.63e-05	200	145	8	M8217
Coexpression	PARENT_MTOR_SIGNALING_UP	MED18 BBS4 DBT CRYL1 THADA HEATR6 FAM120C OSGEPL1 CD86 PEX5 SLC4A4 PCBP2 NCKAP1L	1.70e-05	567	145	13	M16909
ToppCell	droplet-Marrow-BM-1m-Myeloid-basophil\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ANK1 PKD1L2 MET MYOF GVINP1 DNAH11	2.11e-05	168	148	6	2e88d9cb7c80a4656fab290db8b45a5a0599d769
ToppCell	facs-Pancreas-Exocrine-3m-Epithelial-pancreatic_B_cell\|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CELF5 TMPRSS4 F8 CRHBP FANCA SLC38A2	2.57e-05	174	148	6	f1fe1f4216748a9562dd03bd48c70b23c7ff4d1d
ToppCell	TCGA-Head_and_Esophagus-Solid_Tissue_Normal-Head_and_Neck-Head_and_Neck_normal_tissue\|TCGA-Head_and_Esophagus / Sample_Type by Project: Shred V9	GPD1 AMPD1 MYL3 SLC27A6 CLCNKB AGBL1	2.83e-05	177	148	6	675003fbecee1b86919d1a6eeb268e1ca298f714
ToppCell	TCGA-Head_and_Esophagus-Solid_Tissue_Normal-Head_and_Neck\|TCGA-Head_and_Esophagus / Sample_Type by Project: Shred V9	GPD1 AMPD1 MYL3 SLC27A6 CLCNKB AGBL1	2.83e-05	177	148	6	72d144289167f200ac9f006d130de31e45568484
ToppCell	facs-Brain_Non-Myeloid-Striatum-24m-Mesenchymal-ependymal_cell\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CACNA1S TCN1 COL6A5 TSHR LRRC71 DNAH11	2.92e-05	178	148	6	b1db59344c074c7c80169fc2c5cd5fc89f3fe463
ToppCell	facs-Brain_Non-Myeloid-Striatum-24m-Mesenchymal-Ependyma\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	CACNA1S TCN1 COL6A5 TSHR LRRC71 DNAH11	2.92e-05	178	148	6	579cdc14f28b459e200ae2102e0bd4df8a2c0dcb
ToppCell	droplet-Lung-nan-21m-Myeloid-Ccr7+_Dendritic\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ZDHHC2 CACNA1S MYL2 TCN1 RYR3 CD86	3.01e-05	179	148	6	d78eacf47847a50888dd16c35bed9b7afc80010f
ToppCell	3'_v3-bone_marrow-Myeloid_Mac-Erythrophagocytic_macrophages\|bone_marrow / Manually curated celltypes from each tissue	PABPC4 LIPA NYNRIN PEX5 RAB3IL1 GGPS1	3.11e-05	180	148	6	daf69a548ed7c6f285a6adcff00f99aa22f9d6a5
ToppCell	droplet-Limb_Muscle-nan-3m-Mesenchymal-skeletal_muscle_cell\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	GPD1 CACNA1S AMPD1 MYL2 MYL3 ANK1	3.30e-05	182	148	6	edfc598b7199ca1d8a399b264ab863c299b1eede
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Degenerative_Proximal_Tubule_Epithelial_Cell\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	GPD1 SLC13A3 ABCC6 CRYL1 SLC4A4 FHIT	3.84e-05	187	148	6	3ae3b8de1a195d4d5057cf3c64fcdb5f48681ce5
ToppCell	renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_1\|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group	TMPRSS4 MYO5C MET MYOF CLCNKA ABCA6	3.84e-05	187	148	6	f124d2c699b717b7c02a1a70493f515b83dc2f4c
ToppCell	368C-Epithelial_cells-Epithelial-E_(AT2)\|368C / Donor, Lineage, Cell class and subclass (all cells)	CLIC3 ABCC6 MYO5C MET FLRT3 SLC4A4	4.08e-05	189	148	6	6f2322d017b74a1757c81d6e06f50ead8c3dd0cc
ToppCell	systemic_lupus_erythematosus-managed-Hematopoietic-progenitor_cell\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	REXO5 SLC27A6 CRHBP RYR3 CLCNKB NYNRIN	4.08e-05	189	148	6	6687a93ac8540ece5fd762f6f77c1f25f159195b
ToppCell	COVID-19-lung-Secretory\|lung / Disease (COVID-19 only), tissue and cell type	TCN1 TMPRSS4 MYO5C MET SERPINB5 SLC4A4	4.08e-05	189	148	6	84d48e3ed25bebb8bb8074b3a2c5e2e88cff7f25
ToppCell	368C-Epithelial_cells-Epithelial-E_(AT2)-\|368C / Donor, Lineage, Cell class and subclass (all cells)	CLIC3 ABCC6 MYO5C MET FLRT3 SLC4A4	4.08e-05	189	148	6	926b5fa3064b501a57ba78583e8af33532add455
ToppCell	IPF-Epithelial-Basal\|IPF / Disease state, Lineage and Cell class	TMPRSS4 MET CYP4Z2P SERPINB5 FLRT3 SLC4A4	4.20e-05	190	148	6	ea19e9ce954f2dfde97388db9695325cd92ab88f
ToppCell	Fibroblasts-CD55+_Fibroblasts\|Fibroblasts / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues	ABCC6 DENND3 MET CRYL1 VPS13A HAS1	4.20e-05	190	148	6	b4088128f5acf53f43244c9af9fe44e033f1a57a
ToppCell	368C-Epithelial_cells\|368C / Donor, Lineage, Cell class and subclass (all cells)	CLIC3 ABCC6 MYO5C MET FLRT3 SLC4A4	4.20e-05	190	148	6	459811e88d3001816c2d89034e0921c24918c17f
ToppCell	COVID-19-lung-Secretory\|COVID-19 / Disease (COVID-19 only), tissue and cell type	TCN1 TMPRSS4 MYO5C MET SERPINB5 SLC4A4	4.45e-05	192	148	6	59261098ccb52306f837f632ebaea45b90ad30fe
ToppCell	critical-Epithelial-Secretory\|Epithelial / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls	GPI PABPC4 SLC38A2 MET MYOF SLC4A4	4.99e-05	196	148	6	dbf14f5851c2b779a8b35e820c4584ea9096e49d
ToppCell	Smart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-C\|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	GPD1 ENDOD1 SLC13A3 CRHBP CDC42EP2 TMEM63A	4.99e-05	196	148	6	77feb22fd0b0b1df03375da472134412e9e69c90
ToppCell	saliva-Severe-critical_progression_d28-40-Epithelial-Epithelial,_Airway-secretory_cell\|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)	ENDOD1 USP43 MYO5C MYOF FLRT3 SLC4A4	5.14e-05	197	148	6	d6c9da7a3a6d2bcb13e2fc6605c8a59e7fb121c5
ToppCell	saliva-Severe-critical_progression_d28-40-Epithelial-Epithelial,_Airway-secretory_cell-Epi-Secretory\|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)	ENDOD1 USP43 MYO5C MYOF FLRT3 SLC4A4	5.14e-05	197	148	6	80b05c8ad9c1edc5dea3236079372475431343fe
ToppCell	COVID-19_Severe-PLT_0\|World / Disease Group and Platelet Clusters	GPI ENDOD1 ANK1 COMT PPP6R1 LIPA	5.28e-05	198	148	6	d508d69d8de233573aee14f17dd8ef054654aa54
ToppCell	Bronchial-NucSeq-Epithelial\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	ST7 MYO5C MET SLC4A4 FHIT AGBL1	5.43e-05	199	148	6	5f7da3eab58ace6cddb3179a415cd839d5767958
ToppCell	Bronchial_Brush-Epithelial-Basal_2\|Bronchial_Brush / Tissue, Lineage and Cell class of Lung Cells from 10X	PABPC4 SLC38A2 MET MYOF SERPINB5 FLRT3	5.58e-05	200	148	6	1fa29a9f42987549a75dffeb177099458f7cca88
Disease	nephrogenic diabetes insipidus (implicated_via_orthology)	CLCNKA CLCNKB SLC4A4	1.25e-05	10	141	3	DOID:12387 (implicated_via_orthology)
Disease	Bartter disease type 4B	CLCNKA CLCNKB	2.27e-05	2	141	2	cv:C4310805
Disease	Bartter disease type 3 (implicated_via_orthology)	CLCNKA CLCNKB	2.27e-05	2	141	2	DOID:0110144 (implicated_via_orthology)
Disease	BARTTER SYNDROME, TYPE 4B, NEONATAL, WITH SENSORINEURAL DEAFNESS	CLCNKA CLCNKB	2.27e-05	2	141	2	613090
Disease	BARTTER SYNDROME, TYPE 4B	CLCNKA CLCNKB	2.27e-05	2	141	2	C2751312
Disease	BARTTER SYNDROME, TYPE 4B, NEONATAL, WITH SENSORINEURAL DEAFNESS	CLCNKA CLCNKB	2.27e-05	2	141	2	C4310805
Disease	Bartter disease type 4b (is_implicated_in)	CLCNKA CLCNKB	2.27e-05	2	141	2	DOID:0110146 (is_implicated_in)
Disease	Bartter disease (implicated_via_orthology)	CLCNKA CLCNKB	2.27e-05	2	141	2	DOID:445 (implicated_via_orthology)
Disease	X-21258 measurement	CYP2C19 CYP2C9	6.78e-05	3	141	2	EFO_0800802
Disease	free androgen index	USP43 TMPRSS4 MET THADA CLYBL NYNRIN FHIT DNMBP L3MBTL3	8.26e-05	374	141	9	EFO_0007005
Disease	triclosan measurement, 8-hydroxydeoxyguanosine measurement	USP43 CLCA1	1.35e-04	4	141	2	EFO_0801078, EFO_0801081
Disease	Severe intellectual disability and progressive spastic paraplegia	AP4M1 AP4B1	1.35e-04	4	141	2	C4755264
Disease	hypertrophic cardiomyopathy 10 (implicated_via_orthology)	MYL2 MYL10	2.25e-04	5	141	2	DOID:0110316 (implicated_via_orthology)
Disease	non-alcoholic fatty liver disease	MYL2 POLR3A MET SLC4A4 DNMBP L3MBTL3	2.50e-04	182	141	6	EFO_0003095
Disease	thigh muscle volume	CACNA1S CLCNKB	3.36e-04	6	141	2	EFO_0020107
Disease	Bartter syndrome	CLCNKA CLCNKB	3.36e-04	6	141	2	cv:C0004775
Disease	Exfoliation Syndrome	AGPAT1 POMP	3.36e-04	6	141	2	C0206368
Disease	hepatocyte growth factor receptor measurement	MET ABCA6	4.69e-04	7	141	2	EFO_0008153
Disease	10-undecenoate 11:1n1 measurement	CYP4Z1 CYP4Z2P	4.69e-04	7	141	2	EFO_0021099
Disease	urinary bladder cancer (is_implicated_in)	CYP2C9 XDH FANCA FHIT	4.91e-04	76	141	4	DOID:11054 (is_implicated_in)
Disease	X-11787 measurement	CYP2C9 CLYBL	6.23e-04	8	141	2	EFO_0021258
Disease	cerebellar ataxia (implicated_via_orthology)	AARS2 VPS13A	6.23e-04	8	141	2	DOID:0050753 (implicated_via_orthology)
Disease	neuroimaging measurement	SLC27A6 LRRC49 SLC13A3 MSH5 DENND3 PPP4R3A SLC35D1 JAK1 THADA AKAP10 L3MBTL3 AGBL1 EIF2AK3 DNAH11	6.24e-04	1069	141	14	EFO_0004346
Disease	multiple myeloma (is_marker_for)	XDH CBL CD86	6.79e-04	36	141	3	DOID:9538 (is_marker_for)
Disease	X-11308 measurement	CYP2C19 CYP2C9	1.21e-03	11	141	2	EFO_0800693
Disease	thymol sulfate measurement	CYP2C19 CYP2C9	1.45e-03	12	141	2	EFO_0021170
Disease	renal sinus adipose tissue measurement	ARHGAP20 L3MBTL3	1.71e-03	13	141	2	EFO_0004864
Disease	serum metabolite measurement	CYP2C9 COMT SLC13A3 PKD1L2 CRAT SLC38A2 PHKB CYP4Z2P LRPPRC FHIT ARHGAP20 AGBL1	1.98e-03	945	141	12	EFO_0005653
Disease	non-high density lipoprotein cholesterol measurement	DNAJC13 MYL2 COMT VN1R1 THADA LIPA ABCA6 NYNRIN L3MBTL3 DNAH11	2.31e-03	713	141	10	EFO_0005689
Disease	ovarian cancer (is_implicated_in)	COMT FANCA JAK1	2.46e-03	56	141	3	DOID:2394 (is_implicated_in)
Disease	hypertension (is_implicated_in)	CYP2C9 COMT XDH CLCNKB	2.76e-03	121	141	4	DOID:10763 (is_implicated_in)
Disease	asthma (biomarker_via_orthology)	CD86 PRMT5 CCR8	2.86e-03	59	141	3	DOID:2841 (biomarker_via_orthology)
Disease	low density lipoprotein cholesterol measurement, physical activity	ABCA6 NYNRIN DNAH11	3.92e-03	66	141	3	EFO_0003940, EFO_0004611
Disease	renal cell carcinoma (is_implicated_in)	COMT MET FHIT	4.45e-03	69	141	3	DOID:4450 (is_implicated_in)
Disease	vitiligo (is_implicated_in)	COMT NLRP1	4.49e-03	21	141	2	DOID:12306 (is_implicated_in)
Disease	lung non-small cell carcinoma (is_implicated_in)	MSH5 CBL JAK1 FHIT	4.52e-03	139	141	4	DOID:3908 (is_implicated_in)
Disease	apolipoprotein B measurement	DNAJC13 ANK1 COMT MYOF THADA ABCA6 NYNRIN L3MBTL3 DNAH11	4.69e-03	663	141	9	EFO_0004615

Protein segments in the cluster

Peptide	Gene	Start	Entry
MGFQKFSPFLALSIL	CALCA	1	P06881
KPGFNISILKIFITM	CYP4Z2P	141	Q8N1L4
ATSMAIPLIGKFLLF	CHRND	301	Q07001
FLSAAINFQPKMGEL	BBS4	326	Q96RK4
ILQMFVPFGHVISAK	CELF3	396	Q5SZQ8
LGVLAVLFVKFSMPS	COPS3	56	Q9UNS2
KGLMHRDLKPSNIFF	EIF2AK3	931	Q9NZJ5
TMEKVFLPGFLSSNL	AKAP10	486	O43572
QRLFMVLLLKGVPFT	CLIC3	26	O95833
SVKMNVLLFAPGLLF	ALG3	206	Q92685
ASFMGHLPIVKNLLQ	ANK1	411	P16157
KKIFFSLPQIAADLM	GVINP1	1431	Q7Z2Y8
GLFLQVAPLSVMAKS	FLRT3	16	Q9NZU0
PFITKNLLHNEMFIL	ABCA6	211	Q8N139
TKLFLILAKMFPHVQ	AP4B1	256	Q9Y6B7
LLTIFGNFLEKPVVM	DNAH11	571	Q96DT5
MLAFAARTVVKPLGF	CRAT	1	P43155
LSMFTGPHKLVQKRF	DNMBP	1111	Q6XZF7
KNPFLDFLQKGLMIS	AMPD1	631	P23109
MAFLLSGAAPLKIQA	CD86	16	P42081
GPLHLVFNMKSLQIV	DENND3	161	A2RUS2
SFLMQLLGQQKIKHP	PHYKPL	341	Q8IUZ5
NFFKMNLLLHVSPVC	AGBL1	1096	Q96MI9
MISQFFILSSKGDPL	AP4M1	1	O00189
FSFHLKGRKLEQPMN	CLYBL	151	Q8N0X4
LIPFVETAMGLLNFK	CLYBL	166	Q8N0X4
LRKEMSLAKLGFFPQ	RAB3IL1	366	Q8TBN0
KQELQPFLFGLFLSM	OR7A2P	21	Q8NGA2
FPSLGDLMSHLKKQI	JAK1	516	P23458
DAFFKTLSNMGILPA	PPP4R3A	351	Q6IN85
PINFTVFLTMFGEKL	MYL2	76	P10916
IMSIKLGPALKIFNS	L3MBTL3	751	Q96JM7
LGPALKIFNSILMFK	L3MBTL3	756	Q96JM7
SFMPFFLKAASLGLL	DBT	306	P11182
LQKIMGFALPLFHAR	MOGAT1	251	Q96PD6
FPLIQTMHSNLAGKI	PABPC4	576	Q13310
MLILTKTAGVFFKPS	OSGEPL1	1	Q9H4B0
LTGPTNAIFKAFAMI	PCBP1	61	Q15365
FGIPVSSMSKLLQFL	INTS1	1251	Q8N201
FETFLPMLQHISKNK	MYL3	111	P08590
FAGLHFFNPVPVMKL	HADH	166	Q16836
LMGFIATPFIKLFQL	ENDOD1	331	O94919
GLTHNPELQKFLFVM	OR4C45	11	A6NMZ5
TKFILLGLSDHPQMK	OR5A2	11	Q8NGI9
PLMKLAGHFTQDKAL	PEX5	16	P50542
SFSPLGVLLKMIHNA	NLRP1	1211	Q9C000
GILAMKPHFLKINVS	DPY19L1	321	Q2PZI1
ALLAVLKKFMFHGLP	HEATR6	261	Q6AI08
LKKFMFHGLPGLNIE	HEATR6	266	Q6AI08
ANLPALVLKIMSGTF	NEK8	206	Q86SG6
LLGPKALFAFMALSF	NCKAP1L	361	P55160
PNSLHLKFKETNLVM	LRRC49	466	Q8IUZ0
VFMPGNKVLLHLNLI	LRRC71	466	Q8N4P6
KLKEVQMHSFPLQFT	LRPPRC	396	P42704
SIVFTKLTPFMLGAL	GPI	476	P06744
GLKEMVFPSSRNLFL	F8	1181	P00451
NPELVALVKHLSKMF	GGPS1	281	O95749
PINFTVFLTMFGEKL	MYL10	136	Q9BUA6
LPKMLQNFLSTHKAI	OR12D2	76	P58182
TAFFPDLVNMLVLGK	PADI3	581	Q9ULW8
GMKAPATLFTFLVLL	TMEM63A	691	O94886
FLNLLTLKPGEAMFL	MPI	256	P34949
KAMLRPALFANLFGV	MYBBP1A	126	Q9BQG0
FPKHTFLMNGLIQGV	MFSD14A	66	Q96MC6
SMFVTQPLKVLGFAA	PKD1L2	1866	Q7Z442
MVFLLKGQQASPFVL	MED18	56	Q9BUE0
LPKMLQNFLSAHKAI	OR12D1	76	P0DN82
FILMGLFRQSKHPAL	OR2T29	16	Q8NH02
LAGPTNAIFKAFAMI	PCBP2	61	Q15366
QGLFAPLKLQMEFKA	POMP	71	Q9Y244
QFLGTMAPNFTILIK	P2RX2	186	Q9UBL9
FILQPIHNLLMGDTK	COMT	41	P21964
MSFRFGQHLIKPSVV	FHIT	1	P49789
SFLQGKFHLLPGTMV	CDC42EP2	56	O14613
FPGTHNKLLKNLAFM	CYP2C19	226	P33261
KTNPLMKLINHSFID	MT-CYB	6	P00156
MSPNFKLQCHFILIF	CRHBP	1	P24387
LNSIFKAMLPLFHIA	CACNA1S	186	Q13698
IFTNFKMNILGLLIP	CCR8	196	P51685
FPLFESHMNKLKSAI	FNIP1	356	Q8TF40
QVMFKSDKFLIIPLH	DHX36	511	Q9H2U1
SPGLIKKFQFLMFRL	FANCA	861	O15360
FPALQKFTVLDLGMV	FAAP24	101	Q9BTP7
SPMLNHLKKNFQFIG	COL6A5	91	A8TX70
LTQMFLPFGNIISSK	CELF5	416	Q8N6W0
LGLKRMNFPIFAALL	FAM120C	301	Q9NX05
LKKFGSVFPSLNMAV	BIN3	111	Q9NQY0
KGFPVLSKMHQRLIF	PRMT5	241	O14744
LFKLFQHPSMAIIKG	DNAJC13	566	O75165
GLLPAKFLALVTMNQ	HAS1	471	Q92839
QHKGLVDKFPLFMAV	GPD1	311	P21695
LIFSHMLAELKGIFP	CBL	156	P22681
LMPSKLFAGLVHVKQ	CRYL1	126	Q9Y2S2
FPGTHNKLLKNVAFM	CYP2C9	226	P11712
SKAFHLLQKLLTMDP	CDK8	306	P49336
ALQGFKITPSHAMKI	SNRPB2	206	P08579
MLPIANAILKSLFGQ	SLC13A3	151	Q8WWT9
GFHTKLIMLFPQKLR	SACS	3956	Q9NZJ4
FNPILDMLAALKKGI	PHKB	631	Q93100
MVKDRLLPFTFAGNL	NYNRIN	911	Q9P2P1
LPMFTFTAGNALKAI	PARL	301	Q9H300
VPILGFKKFMLTHLV	MSH5	206	O43196
LQLPLKTKAFFMLDG	MET	811	P08581
LDMLFFLNQKGPLTK	ARHGAP20	381	Q9P2F6
SGLAIILFIKTMFHP	THADA	251	Q6YHU6
LIASFGNFLPKTKMA	TAS2R3	251	Q9NYW6
TKHMLKILNFTGPLF	TMEM131L	431	A2VDJ0
SPLFKAKMVLGFALI	ABCC6	66	O95255
IPMNIGTGLFKLLHK	POLR3A	1351	O14802
FIPFVQSLMDLKDLG	SETX	411	Q7Z333
IIELPFQNKHLSMFI	SERPINB5	216	P36952
FQNKHLSMFILLPKD	SERPINB5	221	P36952
VFKPDTFHGLKNLMQ	PRELP	211	P51888
ITGLFSTKKLNLPMF	SLC35D1	121	Q9NTN3
PAFMLKKIVLGNFSS	SPG21	156	Q9NZD8
LLTHQFPELMGVFAK	ST7	531	Q9NRC1
SLLFVNAGMNQFKPI	AARS2	71	Q5JTZ9
MGFQKFSPFLALSIL	CALCA	1	P01258
MGPFKSSVFILILHL	CLCA1	1	A8K7I4
LFLGKVGPFVHLSVM	CLCNKA	161	P51800
LFLGKVGPFVHLSVM	CLCNKB	161	P51801
KPGFNISILKIFITM	CYP4Z1	141	Q86W10
AKAFISLPSFQRHMI	ZNF564	231	Q8TBZ8
KNFSEIHPGMLLIGF	PDCD11	721	Q14690
KLSTLVKFPLSGLNM	USP43	601	Q70EL4
QFLFHSLAMSKPELI	ZNF695	51	Q8IW36
FVKDLAPFMILNSLG	VPS13A	1871	Q96RL7
GPSFLQMRIKHLLKS	RLF	211	Q13129
VLQPFHFRAGTMSKL	RMC1	176	Q96DM3
SMLPFKRGAFHLAVQ	AGPAT1	186	Q99943
PMKSVQKIGALFFLL	SLC38A2	466	Q96QD8
LFQFELGKLKNAMPL	RYR3	1456	Q15413
LGKLKNAMPLSAAIF	RYR3	1461	Q15413
LKRLFKSFGPVQSMT	REXO5	521	Q96IC2
ATFLKLAGPQLVQMF	PSMC3	246	P17980
AAAQVLPALMGKTFL	TCN1	286	P20061
ALANSMVLFFKGIPQ	VN1R1	91	Q9GZP7
IALMKLQFPLTFSGT	TMPRSS4	291	Q9NRS4
LPSVVNFFAAITKMK	RRN3P1	131	Q2M238
LNPVFMASGAKLTLV	XDH	361	P47989
GSFLPALVLKMQLFL	TTC21A	211	Q8NDW8
LNPLLASFFSKVMGI	PPP6R1	116	Q9UPN7
LMFSTVKLKNLLAPG	TMEM241	231	Q24JQ0
LKLGTAFFMVLFQKP	SLC30A5	66	Q8TAD4
KVGMKDLALFFSLNP	WASHC4	701	Q2M389
LTGLSVFMAPILKFI	SLC4A4	886	Q9Y6R1
GLPDTQAKFHIMFLF	ZDHHC2	201	Q9UIJ5
AGMVVLHFLQKLLFP	SLC27A6	11	Q9Y2P4
PMVFKAQLFALTGVQ	USP14	26	P54578
FSVPGSMKLHNLISK	TRRAP	3426	Q9Y4A5
QLFVPIMFALLKAGT	TARM1	151	B6A8C7
QMKVLFVGNSFLLTP	PRO0461	26	Q9UI25
PLLKFLGIFNTGLKM	TSHR	126	P16473
AKRIKMFFALGPVAS	LIPA	191	P38571
EMIQIPSSFKLGFLN	MYO5C	1726	Q9NQX4
NFPSSVLFMKVFLPK	MYOF	1351	Q9NZM1